Eikon Therapeutics is pioneering a new method of drug discovery based on tracking and measuring
the movement of individual proteins in living cells.

Eikon’s live cell imaging drug discovery platform is built on groundbreaking innovations from its founders who pioneered the field of in vivo single-molecule microscopy, and whose work was awarded the Nobel Prize in Chemistry in 2014.

• Industry

  • 3D Imaging
  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2019

• Founders

  • Eric Betzig
  • Robert Tjian
  • Luke Lavis
  • Xavier Darzacq

  LUX Partners

  • Adam Goulburn
  • Josh Wolfe

• Latest Tweets

  • We are thrilled to announce a new addition to our Board of Directors: Robin L. Washington. We are honored to have s… https://t.co/NAg2jQOpf7@EikonTX - 11:37 AM May 16th
  • What's the future hold for #biotech in the Bay Area? Eikon CFO Freddie Bowie will join @SFBusinessTimes reporter… https://t.co/J0Sb9Pur7x@EikonTX - 06:58 PM May 12th
  • What better way to build teamwork and a sense of community than to build bikes for children experiencing foster car… https://t.co/SWyMtKM1SD@EikonTX - 06:48 PM May 12th